drugset
drugset / Trial / NCT01321437

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

NCT01321437 ↗

Phase 2 Completed 11 enrolled University of California, Irvine Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.

Timeline

Start
2011-12
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral

Indications

melanoma